Description:
This product is a recombinant rhesus IgG1 chimeric version of the broadly neutralizing human monoclonal antibody 3BNC117, originally derived from an HIV-infected individual. The 3BNC117 antibody targets the CD4 binding site (CD4bs) on the HIV-1 Envelope (Env) glycoprotein, a highly conserved and functionally critical epitope across HIV-1 subtypes. This rhesus chimeric format preserves the original antigen specificity while replacing the human Fc region with rhesus IgG1 to ensure compatibility with macaque immune effector functions in nonhuman primate (NHP) models.
This version lacks LS (M428L/N434S) Fc mutations, resulting in wild-type Fc effector activity and half-life, making it suitable for studies where native Fcγ receptor engagement and immune clearance are desired.
Key Features:
- NHP-Compatible: Engineered with a rhesus IgG1 Fc region for use in rhesus macaque models
- Broadly Neutralizing: Retains full specificity and neutralization breadth of human 3BNC117.
- No LS Mutations: Standard (wild-type) Fc for studies requiring natural FcγR interactions and clearance kinetics.
- Validated Targeting: Recognizes the conserved CD4bs of HIV-1 Env, suitable for prevention, therapeutic, or reservoir targeting studies.
Applications:
- Passive immunization studies in rhesus macaques
- Preclinical evaluation of bNAbs for HIV prevention or cure strategies
- Pharmacokinetics and Fc function assessments without FcRn-enhancing mutations
- Viral challenge models and immune correlates of protection
Usage Notes:
This antibody is supplied as an unconjugated IgG1. For in vivo use, typical dosing regimens for passive transfer in rhesus macaques range from 10–30 mg/kg, though this should be optimized per study design. Because this version lacks LS mutations, it is ideal for time-course studies where normal IgG clearance rates are desired.
|